-
Glaxo offloads non-core assets in US and Canada
News Pharmaceuticals giant GlaxoSmithKline, which announced back in February its intention to get rid of its Consumer Healthcare OTC brands, has now reached an agreement with Prestige Brands Holdings to sell these non-core US and Canadian brands for £426m cash.
News -
Failed drug tests hit AstraZeneca earnings
News Pharmaceutical giant AstraZeneca has warned earnings will come in at the lower end of expectations after it took a $381.5m hit from failed drug tests.
News -
Fusion IP signs agreement with pharmaceutical company
News Fusion IP, which commercialises university research, has signed an agreement with a pharmaceutical company utilising intellectual property out of the University of Sheffield, for the development of a known drug.
News -
AstraZeneca lays off 1,150 in US, takes one-off charge
News Pharmaceuticals giant AstraZeneca is to cut 1,150 jobs from its sales force in the US, as part of its "ongoing strategy to operate its business more efficiently to best serve patients".
News -
Yule Catto sells pharma division to Vivimed
News Yule Catto, the Essex headquartered polymer business, has sold its pharmaceuticals division, Uquifa, to the Indian firm Vivimed Labs.
News -
AstraZeneca wins approval for new diabetes drug
News The FTSE 100 pharmaceuticals firm, AstraZeneca, has won Europe-wide approval for its diabetes drug Komboglyze.
News -
Depressing drug result for Astra
News An anti-depressant product made by Anglo-Swedish drugs titan AstraZeneca and US partner Targacept has failed to meet its initial target.
News -
Glaxo to pay $3bn to settle with US government
News Drugs giant GlaxoSmithKline is set to pay $3bn to get the US government off its back over the the company's sales and market practices in the past.
News -
A biotech startup already yielding 6.4%
Features Small, innovative companies that can sell their products around the world are exactly what Britain needs. And Tom Bulford's found an excellent example here, which he'll be keeping a very close eye on.
Features